newsfilter
← Latest News
PR Newswire·

Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new two-year data from the Phase 3 CAHtalyst® Pediatric study...